<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Castration-resistant prostate cancer: Treatments targeting the androgen pathway</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Castration-resistant prostate cancer: Treatments targeting the androgen pathway</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Castration-resistant prostate cancer: Treatments targeting the androgen pathway</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Nancy A Dawson, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jerome P Richie, MD, FACS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">W Robert Lee, MD, MS, MEd</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Melinda Yushak, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Jul 07, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1409920"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Androgen deprivation therapy (ADT), either alone or in combination with chemotherapy, is generally the initial treatment for males with metastatic prostate cancer. Standard approaches to ADT include bilateral orchiectomy or medical orchiectomy using a gonadotropin releasing hormone (GnRH) agonist, which may be given alone or in combination with an antiandrogen (combined androgen blockade). (See  <a class="medical medical_review" href="/z/d/html/6951.html" rel="external">"Initial systemic therapy for advanced, recurrent, and metastatic noncastrate (castration-sensitive) prostate cancer"</a>.)</p><p>Despite initial response rates of 80 to 90 percent, nearly all males eventually develop progressive disease following ADT; this is referred to as castration-resistant prostate cancer (CRPC). Contemporary research in males with CRPC has led to the development of multiple agents that improved overall survival in phase III trials  (<a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">table 1</a> and <a class="graphic graphic_table graphicRef127196" href="/z/d/graphic/127196.html" rel="external">table 2</a>).</p><p>Insights into the mechanisms by which androgens stimulate growth of prostate cancer cells is leading to the development of new treatments with clinically significant activity in males with CRPC. These approaches are discussed here.</p><p>Overviews of the management of advanced castration-sensitive prostate cancer and CRPC are presented separately. (See  <a class="medical medical_review" href="/z/d/html/6941.html" rel="external">"Overview of systemic treatment for recurrent or metastatic castration-sensitive prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a>.)</p><p class="headingAnchor" id="H1409939"><span class="h1">MOLECULAR PATHWAYS</span></p><p class="headingAnchor" id="H617152529"><span class="h2">Rationale</span><span class="headingEndMark"> — </span>Contemporary research has demonstrated that androgen-based pathways have a clinically significant role in the progression of CRPC. In addition to androgen production by the adrenal gland and testis, several of the enzymes involved in the synthesis of testosterone and dihydrotestosterone, including cytochrome P450 17-alpha-hydroxysteroid dehydrogenase (CYP17), are highly expressed in tumor tissue [<a href="#rid1">1</a>].</p><p>Collectively, these findings changed the perspective on prostate cancer from what has long been considered an "endocrine" disease to one that is dependent on "autocrine/paracrine" signaling for tumor progression and survival. This understanding has led to the development of drugs that act by inhibiting the enzymes responsible for androgen production, as well as agents that inhibit the androgen receptor.</p><p class="headingAnchor" id="H1409964"><span class="h3">Androgen synthesis inhibitors</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">Abiraterone</a> was developed through screening chemical derivatives of a parent structure of pregnenolone. The structural changes in abiraterone cause potent and irreversible inhibition of CYP17 [<a href="#rid2">2-4</a>]. In preclinical studies, abiraterone was 10 times more potent than <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> as an inhibitor of CYP17 [<a href="#rid4">4</a>]. (See <a class="local">'Abiraterone'</a> below.)</p><p>Although <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">ketoconazole</a> is a more potent inhibitor of the side chain cleavage enzyme, which plays a critical role in adrenal steroidogenesis, patients treated with either of these agents are at risk for adrenal insufficiency and require steroid replacement therapy. The use of ketoconazole is further limited by the potential for drug-drug interactions, particularly with statins and antidepressants. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Ketoconazole'</a>.)</p><p class="headingAnchor" id="H1385299623"><span class="h3">Androgen receptor antagonists</span><span class="headingEndMark"> — </span>Some metastatic and primary prostate tumors retain activation of the androgen receptor in processes that are entirely independent of the androgen ligand. Several mechanisms, including up-regulation of androgen receptor expression through amplification of the androgen receptor gene [<a href="#rid5">5-7</a>], increased sensitivity of the androgen receptor via overexpression of nuclear coactivators [<a href="#rid8">8</a>], and splice variant mutations of the receptor [<a href="#rid9">9,10</a>], have been proposed and may coexist. Importantly, these data suggest that progression of CRPC in some patients may not be effectively treated by a focus solely on ligand-directed therapy.</p><p><a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">Enzalutamide</a>, a small molecule antagonist of the androgen receptor, has important clinical activity and a role in the management of patients with CRPC. (See <a class="local">'Enzalutamide'</a> below.)</p><p class="headingAnchor" id="H617152555"><span class="h2">Resistance</span><span class="headingEndMark"> — </span>Although both androgen synthesis inhibitors and androgen receptor antagonists can significantly alter the natural history of CRPC, progressive disease and resistance to these agents will eventually develop in most cases. The mechanisms for resistance are not fully understood and are the subject of ongoing research [<a href="#rid11">11,12</a>].</p><p>One possible mechanism to explain the lack of activity of these agents in approximately one-third of patients and the presence of resistance in almost all of those who do respond is the presence of variants in the androgen receptor [<a href="#rid13">13,14</a>]. The androgen receptor isoform splice variant 7 (AR-V7) lacks the binding site for androgen while retaining the activating site that stimulates tumor growth.</p><p>Data on the importance of AR-V7 come from the following reports:</p><p class="bulletIndent1"><span class="glyph">●</span>In a single-institution study of 202 males with metastatic CRPC who were starting therapy with either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>, all patients were assessed for the presence or absence of circulating tumor cells (CTCs), and those with CTCs present were assessed for the presence or absence of AR-V7 in those cells [<a href="#rid14">14</a>]. Responses to hormonal therapy were observed in 40 of 53 (75 percent) of those patients without CTCs, 59 of 113 (52 percent) of those with CTCs but without AR-V7, and 5 of 36 (14 percent) of those with CTCs that contained AR-V7. Furthermore, the duration of progression-free survival (PFS) for these groups decreased with the presence of AR-V7 (11.3, 6.2, and 2.1 months for the three groups, respectively). Overall survival was significantly shorter for those with AR-V7 (28.7, 29.5, and 11.2 months, respectively).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Additional information comes from the multicenter, prospective PROPHECY study, in which 118 males with metastatic CRPC starting therapy with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> or <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were assessed for baseline CTC AR-V7 [<a href="#rid15">15</a>]. Detection of CTC AR-V7 by either of two different assays was independently associated with shorter PFS and overall survival, as well as fewer confirmed prostate-specific antigen (PSA) responses (0 to 11 percent versus 26 to 28 percent in those who were AR-V7 negative) and soft tissue responses (0 to 6 percent versus 21 to 25 percent in those who were AR-V7 negative).</p><p></p><p>Although the AR-V7 splice variant predicts relative resistance to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>, preliminary evidence suggests that it is not associated with resistance to <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> chemotherapy [<a href="#rid16">16</a>]. Standardized, validated, and commercially available assays for AR-V7 are now available. The optimal use of AR-V7 testing is not yet clear, but it is likely to be in the abiraterone- or enzalutamide-resistant setting, in which consideration is being given to the use of a second androgen-receptor-targeted drug versus proceeding with chemotherapy. However, in practice, most males prefer to try another oral agent before moving on to chemotherapy, and responses are possible even in the presence of the AR-V7 splice variant.</p><p class="headingAnchor" id="H3407941202"><span class="h2">Clinical role</span><span class="headingEndMark"> — </span>The clinical role of treatments for metastatic CRPC that target the androgen pathway is evolving. Contemporary research in males with CRPC has led to the development of multiple agents that have significantly improved overall survival in phase III trials  (<a class="graphic graphic_table graphicRef127196" href="/z/d/graphic/127196.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">table 1</a>). These agents have not been compared with each other, and the appropriate sequencing of them in males with advanced disease is not established. The factors affecting the choice and sequence of therapies in the setting of CRPC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a>.)</p><p class="headingAnchor" id="H2564519118"><span class="h1">PATIENTS WITH METASTATIC CRPC</span></p><p class="headingAnchor" id="H1409980"><span class="h2">Abiraterone</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">Abiraterone</a> is an orally administered small molecule that irreversibly inhibits the products of the cytochrome P450 17-alpha-hydroxysteroid dehydrogenase (<em>CYP17</em>) gene (including both 17,20-lyase and 17-alpha-hydroxylase). In doing so, abiraterone blocks the synthesis of androgens in the tumor, as well as in the testes and adrenal glands.</p><p class="headingAnchor" id="H1385299281"><span class="h3">Efficacy</span><span class="headingEndMark"> — </span>The activity of <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> was established in two phase III trials in males with metastatic CRPC, the first in patients who had received prior <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> [<a href="#rid17">17-19</a>] and the other in patients with chemotherapy-naïve disease [<a href="#rid20">20,21</a>].</p><p class="headingAnchor" id="H1135663811"><span class="h4">Prior docetaxel chemotherapy</span><span class="headingEndMark"> — </span>In the first phase III trial, 1195 males who had previously been treated with a docetaxel-containing chemotherapy regimen were randomly assigned in a 2:1 ratio to <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> (1000 mg/day) plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (5 mg twice a day) or to placebo plus prednisone [<a href="#rid17">17-19</a>]. Treatment was continued until disease progression. Disease progression was determined by a composite of worsening pain and decline in performance status, as well as objective progression on scans and by prostate-specific antigen (PSA) rises. A rise in PSA on therapy (or a lack of decline) was not the sole criterion for discontinuation of therapy. The trial was terminated based upon an interim analysis when results exceeded prespecified criteria.</p><p>The final analysis of overall survival was conducted at a median follow-up of 20 months. Overall survival, the primary endpoint of the trial, was significantly increased with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> compared with placebo (median 15.8 versus 11.2 months, hazard ratio [HR] 0.74, 95% CI 0.64-0.86). Benefits were similar in all subsets based upon preplanned analyses. Statistically significant improvements were also seen in time to PSA progression, radiologic progression-free survival (PFS), and PSA response rate (8.5 versus 6.6 months, 5.6 versus 3.6 months, and 29.5 versus 6.5 percent, respectively). Although patients with liver or lung metastases had a worse prognosis than those with disease limited to bone and lymph nodes, those receiving abiraterone did have similar improvement in overall survival compared with placebo (median 12.9 versus 8.3 months) [<a href="#rid22">22</a>].</p><p>Secondary analyses from the phase III trial focused on the impact of <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> compared with placebo on symptoms due to bone metastases [<a href="#rid19">19</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Overall, approximately 90 percent of patients had bone metastases, and 41 percent of patients with bone metastases had clinically significant pain secondary to these metastases.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>There was a statistically significant improvement in the percentage of patients with palliation of pain intensity due to bone metastases with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> compared with placebo plus prednisone (45 versus 29 percent), and palliation of pain intensity was achieved more rapidly (5.6 versus 13.7 months). Similar benefits for the combination of abiraterone plus prednisone were seen when the impact of pain on activities of daily living was assessed.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Skeletal-related events (pathologic fracture, spinal cord compression, or palliative radiation therapy and/or surgery to bone) were seen in 23 and 25 percent of all patients treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> and placebo versus prednisone, respectively. However, there was a statistically significant increase in the time to first skeletal-related event (median 25 versus 20 months for the entire study population).</p><p></p><p>Increased isotope uptake on bone scan suggestive of progressive disease should be interpreted with caution when patients are started on therapy with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>. In a phase II study, follow-up bone scans obtained three months after treatment initiation were interpreted as worsening in 12 of 23 patients (52 percent) with a decrease in serum PSA of 50 percent or more [<a href="#rid23">23</a>]. In 11 of these 12, subsequent bone scans showed improvement or stabilization of bone disease.</p><p class="headingAnchor" id="H1135663818"><span class="h4">Chemotherapy-naïve patients</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">Abiraterone</a> also delays disease progression and prolongs overall survival in males with CRPC who have not received chemotherapy.</p><p>In a phase III trial, 1088 males with metastatic, asymptomatic or minimally symptomatic CRPC were randomly assigned to <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or placebo plus prednisone [<a href="#rid20">20,21,24</a>]. Patients could not have received prior chemotherapy. The coprimary endpoints of the trial were radiographic PFS assessed by independent review and overall survival.</p><p class="bulletIndent1"><span class="glyph">●</span>The final survival analysis was conducted at a mean follow-up of 49 months [<a href="#rid21">21</a>]. Overall survival was increased with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> compared with placebo plus prednisone (median 34.7 versus 30.3 months, HR 0.81, 95% CI 0.70-0.93). Analysis of overall survival was complicated by the subsequent use of abiraterone in 44 percent of patients assigned to placebo and by the use of other additional active therapy following protocol participation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At the third planned interim analysis, radiographic PFS was significantly increased with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> compared with placebo plus prednisone (median 16.5 versus 8.2 months, HR 0.52, 95% CI 0.45-0.61) [<a href="#rid20">20</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Secondary endpoints that also demonstrated a statistically significant superiority for <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> compared with placebo plus prednisone included time to initiation of cytotoxic chemotherapy, opiate use for cancer-related pain, PSA progression, and decline in performance status. Pain progression and deterioration in health-related quality of life were also significantly delayed with abiraterone [<a href="#rid25">25</a>].</p><p></p><p class="headingAnchor" id="H458937427"><span class="h4">Prior enzalutamide therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">Abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> has only minimal activity in patients who progressed after treatment with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, and for most individuals we suggest not pursuing this therapy.</p><p class="bulletIndent1"><span class="glyph">●</span>The best evidence comes from the phase IV PLATO trial, in which 251 patients who had previously responded to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and then progressed were randomly assigned to either <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> alone or abiraterone plus prednisone and continued enzalutamide [<a href="#rid26">26</a>]. PFS was 5.7 months with abiraterone plus enzalutamide and 5.6 months with abiraterone plus placebo. Overall, there were only four patients in either group with a PSA decline of greater than 50 percent. Hypertension and elevated liver enzymes were more common with combined therapy.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data are also available from the CARD trial, in which 255 patients with metastatic CRPC who had progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and either <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> or <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were randomly assigned to <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> or the other antiandrogen previously received, outcomes were significantly better with cabazitaxel [<a href="#rid27">27</a>]. In the group receiving the androgen receptor inhibitor, the median PFS was only 2.7 months, a PSA response occurred in only 14 percent, and 12 percent had an objective tumor response. (See  <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer", section on 'Third-line cabazitaxel versus androgen signaling therapy'</a>.)</p><p></p><p class="headingAnchor" id="H1410012"><span class="h3">Toxicity</span><span class="headingEndMark"> — </span>The toxicity profile of <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> is, in part, dependent upon its mechanism of action. CYP17, the target of abiraterone, regulates the conversion of pregnenolone and related steroids into androgens and is relatively specific for androgen production. However, there is inhibition of 17-alpha hydroxylase with decreased cortisol and a compensatory rise in adrenocorticotropic hormone (ACTH), which is mediated by a hypothalamic response to partial adrenal inhibition.</p><p>The increased ACTH release can cause increased adrenal mineralocorticoid production, which can lead to hypertension and hypokalemia. When <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> is given without concomitant glucocorticoids, patients typically do not experience clinical adrenal insufficiency since cortisol production is preserved. The effects of mineralocorticoid excess can be attenuated by coadministration with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a>, which reduces ACTH-mediated stimulation of the adrenal glands. However, long-term combined treatment is associated with muscle wasting and weakness.</p><p>In the phase III trial in males who had received prior <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, the incidence of severe (grade 3 or 4) adverse events leading to discontinuation of treatment was similar in those treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> and placebo (10 and 13 percent, respectively) [<a href="#rid17">17,18</a>]. Side effects that were more common with abiraterone included fluid retention and hypokalemia (33 versus 24, and 18 versus 9 percent, respectively). Nonspecific cardiac abnormalities, abnormal liver function tests, and hypertension may also be more common in patients treated with abiraterone (16 versus 12, 11 versus 9, and 11 versus 8 percent, respectively).</p><p>Monthly potassium and blood pressure monitoring are essential to the proper management of patients on <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>. Because the hypertension is mediated by an excess of mineralocorticoids, specific mineralocorticoid antagonists, such as <a class="drug drug_general" data-topicid="8789" href="/z/d/drug information/8789.html" rel="external">eplerenone</a>, may be useful; however, standard antihypertensive therapies are also of benefit.</p><p>Other toxicities include liver dysfunction and, in patients with pre-existing diabetes mellitus, hypoglycemia. In addition, all treatments directed at the androgen receptor have adverse effects on other critical physiologic functions, including the cardiovascular system [<a href="#rid28">28,29</a>]. The decision to use <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> in males with preexisting cardiovascular disease, optimizing cardiovascular risk, and monitoring for potential cardiovascular side effects should include input from cardiologists. (See  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Potential cardiovascular harm'</a>.)</p><p class="headingAnchor" id="H3748587449"><span class="h4">Concurrent glucocorticoid therapy</span><span class="headingEndMark"> — </span>All males receiving <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> should also receive <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to mitigate mineralocorticoid excess. The standard dose is 5 mg twice daily, and we do not suggest using either lower prednisone doses or substituting <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for prednisone.</p><p>The original phase III trial demonstrating the benefit of <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> in CRPC used <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 mg twice daily [<a href="#rid17">17,18</a>], and this is the dose that is recommended in the <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdailymed.nlm.nih.gov%2Fdailymed%2FdrugInfo.cfm%3Fsetid%3Dbe29365a-ed25-44c0-9818-e9016dc95ba6&amp;token=pr2go2phqoLEorLiLEqWVhNeXKn%2B9A3HU3bVLXZv8fp4XXVtTmCV4ITdQeOedJLaJOFsYHNmr%2BK7ZYBoFfS0O09SjxSvQNJMJLTES6mXaHJWpF6xslOQsvSRSrneoVfe&amp;TOPIC_ID=16351" target="_blank">United States prescribing information for abiraterone</a>. The optimal dose of glucocorticoid for use in conjunction with abiraterone was directly tested in a multicenter randomized phase II trial in which 164 males starting abiraterone for CRPC were randomly assigned to one of five glucocorticoid regimens: prednisone at 5 mg twice daily, 5 mg daily, or 2.5 mg twice daily, and <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> at 0.5 mg once daily [<a href="#rid30">30</a>]. The primary endpoint, no mineralocorticoid excess (defined by no ≥grade 2 hypertension  (<a class="graphic graphic_table graphicRef87347" href="/z/d/graphic/87347.html" rel="external">table 3</a>), and no ≥grade 1 hypokalemia  (<a class="graphic graphic_table graphicRef91252" href="/z/d/graphic/91252.html" rel="external">table 4</a>)), was achieved by 71 percent of males receiving prednisone 5 mg twice daily, compared with 37 and 60 percent of those receiving prednisone 5 mg daily or 2.5 mg twice daily, and 70 percent of those receiving dexamethasone. The dexamethasone group had significantly higher rates of adverse metabolic consequences (decrease in bone mineral density, increase in serum insulin), and the authors concluded that the results confirmed the approved use of abiraterone with prednisone 5 mg twice daily.</p><p>Side effects attributable to <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> are limited, as evidenced by the following data:</p><p class="bulletIndent1"><span class="glyph">●</span>A detailed analysis of 2267 patients from the two pivotal phase III trials found that the two most frequent side effects associated with <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> were hyperglycemia and weight gain (7.4 and 4.3 percent), and the incidence of grade 3 or greater side effects was 4.5 percent [<a href="#rid31">31</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the above mentioned randomized phase II trial comparing different doses of <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> (2.5 mg twice daily, 5 mg once daily, or 5 mg twice daily) or <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> (0.5 mg once daily) in males receiving <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> for metastatic CRPC, 29 percent of the 41 males receiving prednisone 5 mg twice daily developed hypertension, and it was grade 3 in 7 percent [<a href="#rid30">30</a>]. Other common side effects in this group included peripheral edema in 20 percent, hypokalemia and weight gain in 10 percent each, and elevated liver function tests in 7 percent.</p><p></p><p class="headingAnchor" id="H899328889"><span class="h3">Dosing of abiraterone</span><span class="headingEndMark"> — </span>The approved dose of <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> is 1000 mg orally, once daily, on an empty stomach, either one hour before or two hours after a meal. A randomized phase II trial comparing the effects of 1000 mg per day fasting with 250 mg per day given after a low-fat breakfast demonstrated similar PSA response, PFS, and pharmacodynamic effects with the lower dose, despite higher trough levels in the higher dose arm [<a href="#rid32">32</a>]. Given the high cost of this agent, these and other data support the use of the smaller abiraterone dose administered with a low-fat breakfast as an alternative to the higher dose given on an empty stomach [<a href="#rid33">33,34</a>], especially for males with a high copay and those who live in resource-poor settings, as it might improve compliance and increase access to treatment [<a href="#rid35">35</a>]. However, there are at least some data linking low trough levels with poorer outcomes in males with metastatic CRPC [<a href="#rid36">36</a>], and larger studies are needed in this important area. Nevertheless, administration of the lower dose, administered with a low-fat breakfast, is supported in updated consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) [<a href="#rid37">37</a>].</p><p class="headingAnchor" id="H1055971685"><span class="h3">Treatment at progression</span><span class="headingEndMark"> — </span>Although the practice of switching between <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> and <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> after progression with the other is common, particularly to delay the initiation of chemotherapy, few data are available to support meaningful benefit from use of enzalutamide after failure of abiraterone, and for most individuals we suggest not pursuing this approach. (See <a class="local">'Prior abiraterone therapy'</a> below.)</p><p>Other options are as follows:</p><p class="bulletIndent1"><span class="glyph">●</span>One option for males with limited disease progression while receiving <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> (PSA elevation and/or limited radiographic progression) is to switch from <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> [<a href="#rid38">38</a>]. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Glucocorticoids'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Retreatment with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> can be associated with response in some patients, although clinical benefit appears to be limited [<a href="#rid39">39-42</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">Enzalutamide</a> appears to retain some activity in patients who have been previously treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> [<a href="#rid27">27,39,42-44</a>]. However, clinical benefit is less than in patients who have not received prior abiraterone, and less than has been seen with alternative therapies such as <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The most extensive data come from a multicenter, single-arm phase IV study in which 214 patients were treated with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, including 145 who were chemotherapy naïve [<a href="#rid44">44</a>]. All patients had been treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> for a minimum of 24 weeks, and all had metastatic disease. The median duration of radiographic PFS, the primary endpoint of the study, was 8.1 months and was similar in those who had received prior chemotherapy and those who were chemotherapy naïve. The overall rate of PSA decline ≥50 percent was 27 percent, and the median time to PSA progression was 5.7 months.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Data are also available from the CARD trial, in which 255 patients with metastatic CRPC who had progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and either <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> or <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were randomly assigned to <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> or the other antiandrogen previously received, outcomes were significantly better with cabazitaxel [<a href="#rid27">27</a>]. In the group receiving the androgen receptor inhibitor, the median PFS was only 2.7 months, a PSA response occurred in only 14 percent, and 12 percent had an objective tumor response.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Other therapies (chemotherapy with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> [if not previously received], <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>, alternative endocrine therapies, immunotherapy) may be appropriate, particularly for males with more extensive disease progression. (See  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a> and  <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer"</a>.)</p><p></p><p class="headingAnchor" id="H3695865934"><span class="h2">Enzalutamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">Enzalutamide</a> is an alternative to <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> for males with metastatic CRPC. Enzalutamide binds to the androgen binding site in the androgen receptor, thereby leading to inhibition of nuclear translocation of the androgen receptor and inhibition of the association of the androgen receptor with nuclear deoxyribonucleic acid (DNA). Phase I/II studies showed that enzalutamide had significant activity in males with CRPC [<a href="#rid45">45,46</a>]. This has led to the assessment of enzalutamide in larger randomized clinical trials.</p><p class="headingAnchor" id="H4402640"><span class="h3">Prior docetaxel chemotherapy</span><span class="headingEndMark"> — </span>In the AFFIRM trial, 1199 males with metastatic CRPC who had received prior docetaxel-based chemotherapy were randomly assigned to either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> (160 mg as a single dose, once daily) or placebo in a two to one ratio (NCT00974311) [<a href="#rid47">47,48</a>]. Concurrent therapy with glucocorticoids was permitted but not required on both treatment arms. The patient population in that trial was heavily pretreated, with approximately 50 percent of patients having received three or more prior endocrine therapies, and 25 percent had been treated with two or more chemotherapy regimens.</p><p>Based upon the results of the planned interim analysis after 520 deaths, the blind was broken, and patients were allowed to cross over from placebo to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> upon progression. Results included the following [<a href="#rid47">47</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Overall survival was significantly increased with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> compared with placebo (median 18.4 versus 13.6 months, HR 0.63, 95% CI 0.53-0.75). The survival benefit was consistent across all subgroups.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">Enzalutamide</a> was significantly better than placebo in all secondary efficacy endpoints, including prostate-specific antigen (PSA) response (&gt;50 percent decrease, 54 versus 2 percent of patients, and &gt;90 percent decrease, 25 versus 1 percent), soft tissue response (29 versus 4 percent), quality of life response (43 versus 18 percent), time to PSA progression (8.3 versus 3.0 months), radiographic PFS (8.3 versus 2.9 months), and time to first skeletal-related event (16.7 versus 13.3 months).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment was well tolerated. For patients treated with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, there was a higher incidence of fatigue (34 versus 29 percent), diarrhea (21 versus 18 percent), hot flashes (20 versus 10 percent), musculoskeletal pain (14 versus 10 percent), and headache (12 versus 6 percent). The one toxicity of potential concern was the development of seizures, which occurred in seven patients (0.9 percent) treated with enzalutamide and no patients assigned to placebo [<a href="#rid49">49</a>]. There was no statistically significant difference in the rate of treatment discontinuation due to adverse events (8 versus 10 percent with placebo).</p><p></p><p>Several secondary analyses of the AFFIRM trial were undertaken:</p><p class="bulletIndent1"><span class="glyph">●</span>Health-related quality of life was significantly improved across all domains with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> compared with placebo, based upon the Functional Assessment of Cancer Therapy-Prostate (FACT-P) scores [<a href="#rid48">48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition, the benefits in overall survival and delayed disease progression associated with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were similar in older adult males (≥75 years) compared with those seen in younger males [<a href="#rid50">50</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Although benefits were independent of glucocorticoid use, the benefits of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were less in patients receiving concomitant glucocorticoids [<a href="#rid51">51</a>]. Further study is needed to determine clinical settings in which the short-term benefits of glucocorticoid use outweigh the potential for adverse effects and inferior oncologic outcomes.</p><p></p><p class="headingAnchor" id="H4402646"><span class="h3">Chemotherapy-naïve</span><span class="headingEndMark"> — </span>The primary data supporting the role of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in chemotherapy-naïve patients come from the large randomized PREVAIL trial in males with known metastatic disease. Data in males without detectable metastatic disease are described in detail below. (See <a class="local">'Enzalutamide'</a> below.)</p><p>In the PREVAIL trial, 1717 males with metastatic disease who had not received prior <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> chemotherapy were randomly assigned to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or placebo [<a href="#rid52">52-55</a>]. The coprimary endpoints of the trial were overall survival and radiographic PFS. The trial was stopped after a planned interim analysis, based upon a survival benefit for patients treated with enzalutamide.</p><p class="bulletIndent1"><span class="glyph">●</span>At the planned interim analysis, with a median duration of follow-up of 22 months, overall survival was significantly increased with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> compared with placebo (median 32.4 versus 30.2 months, HR 0.71, 95% CI 0.60-0.84). An extended analysis at 31 months' follow-up included five months in an open-label extension, during which patients could cross over from placebo to enzalutamide [<a href="#rid55">55</a>]. Median overall survival was significantly increased (35.3 versus 31.3 months, HR 0.77, 95% CI 0.67-0.88).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>At a median follow-up of 22 months for <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and 11 months for placebo, there was a significant decrease in the risk of radiographic progression with enzalutamide (median 20 versus 5.4 months, HR 0.32, 95% CI 0.28-0.36). Time to first skeletal-related event was significantly longer in those treated with enzalutamide (median 31 months for both groups, HR 0.72, 95% CI 0.61-0.84).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Based upon patient responses to the FACT-P questionnaire, quality of life was significantly better with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, with median time to clinically significant deterioration longer in those assigned to enzalutamide compared with placebo (median 11.3 versus 5.6 months, HR 0.62, 95% CI 0.54-0.72).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the latest analysis with greater than five-year follow-up, the median overall survival benefit of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> persisted (median 36 versus 31 months), but there was also a higher rate of fatal treatment-emergent side effects with enzalutamide (6.9 versus 3.8 percent), including fatal cardiovascular events (1.6 versus 0.4 percent) [<a href="#rid56">56</a>].</p><p></p><p>Additional support for the role of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in males with chemotherapy-naïve metastatic CRPC comes from two randomized trials comparing enzalutamide with <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a>:</p><p class="bulletIndent1"><span class="glyph">●</span>In the TERRAIN trial, 375 asymptomatic or minimally symptomatic patients with metastatic disease were randomly assigned to either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> (160 mg/day) or <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> (50 mg/day) [<a href="#rid57">57</a>]. PFS, the primary endpoint of the trial, was significantly longer with enzalutamide compared with bicalutamide (15.7 versus 5.8 months, HR 0.44, 95% CI 0.34-0.57).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the STRIVE trial, 396 males with either metastatic or nonmetastatic disease were randomly assigned to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="9154" href="/z/d/drug information/9154.html" rel="external">bicalutamide</a> [<a href="#rid58">58</a>]. PFS, the primary endpoint of the trial, was significantly longer with enzalutamide compared with bicalutamide (19.4 versus 5.7 months, HR 0.24, 95% CI 0.18-0.32). The data from both of these trials are limited to patients with CRPC, and bicalutamide may continue to have a role in other clinical settings. (See  <a class="medical medical_review" href="/z/d/html/6942.html" rel="external">"Alternative endocrine therapies for castration-resistant prostate cancer", section on 'Older antiandrogens'</a>.)</p><p></p><p class="headingAnchor" id="H3336548058"><span class="h3">Toxicity</span><span class="headingEndMark"> — </span>Fatigue, diarrhea, hot flashes, musculoskeletal pain, and headache are the most common reported adverse effects of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>. Seizures are infrequent, occurring in less than 1 percent of treated patients. In addition, all treatments directed at the androgen receptor have adverse effects on other critical physiologic functions, including the cardiovascular system [<a href="#rid28">28,29,59,60</a>]. The decision to use <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> in males with preexisting cardiovascular disease, optimizing cardiovascular risk, and monitoring for potential cardiovascular side effects should include input from cardiologists. (See  <a class="medical medical_review" href="/z/d/html/6927.html" rel="external">"Side effects of androgen deprivation therapy", section on 'Potential cardiovascular harm'</a>.)</p><p class="headingAnchor" id="H2090427521"><span class="h3">Prior abiraterone therapy</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">Enzalutamide</a> appears to retain some activity in patients who have been previously treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>, although the clinical benefit is less than in patients who have not received prior abiraterone [<a href="#rid39">39,42-44</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>The most extensive data come from a multicenter, single-arm phase IV study in which 214 patients were treated with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, including 145 who were chemotherapy naïve [<a href="#rid44">44</a>]. All patients had been treated with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> for a minimum of 24 weeks, and all had metastatic disease. The median duration of radiographic PFS, the primary endpoint of the study, was 8.1 months and was similar in those who had received prior chemotherapy and those who were chemotherapy naïve. The overall rate of PSA decline ≥50 percent was 27 percent, and the median time to PSA progression was 5.7 months.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Data are also available from the CARD trial in which 255 patients with metastatic CRPC who had progressed on <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> and either <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> or <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> were randomly assigned to <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a> or the other antiandrogen previously received, outcomes were significantly better with cabazitaxel [<a href="#rid27">27</a>]. In the group receiving the androgen receptor inhibitor, the median PFS was only 2.7 months, a PSA response occurred in only 14 percent, and 12 percent had an objective tumor response.</p><p></p><p class="headingAnchor" id="H2305030799"><span class="h3">Treatment at progression</span><span class="headingEndMark"> — </span>As noted above, although the practice of switching between <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> and <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> after progression with the other is common, particularly to delay initiation of chemotherapy, few data are available to support meaningful benefit from use of abiraterone after failure of enzalutamide. We do not routinely use this approach. (See <a class="local">'Prior abiraterone therapy'</a> above.)</p><p>Other therapies (taxane-based chemotherapy using either <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a> [if not previously received] or <a class="drug drug_general" data-topicid="15577" href="/z/d/drug information/15577.html" rel="external">cabazitaxel</a>, alternative endocrine therapies, immunotherapy) may be more appropriate, particularly for males with more extensive disease progression. (See  <a class="medical medical_review" href="/z/d/html/6945.html" rel="external">"Chemotherapy in advanced castration-resistant prostate cancer"</a> and  <a class="medical medical_review" href="/z/d/html/6937.html" rel="external">"Immunotherapy for castration-resistant prostate cancer"</a>.)</p><p>For patients not previously treated with <a class="drug drug_general" data-topicid="9381" href="/z/d/drug information/9381.html" rel="external">docetaxel</a>, limited data from the phase III PRESIDE trial suggest there might be benefit for continued <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in conjunction with docetaxel [<a href="#rid61">61</a>]. In this trial, 687 patients with chemotherapy-naïve metastatic CRPC and disease progression on androgen deprivation therapy (ADT) alone all received open-label enzalutamide plus continued ADT; those with a PSA response ≥50 percent at week 13 and later progression (n = 273) received docetaxel plus <a class="drug drug_general" data-topicid="9808" href="/z/d/drug information/9808.html" rel="external">prednisolone</a> and were randomized to continue enzalutamide or switch to placebo. In a preliminary report presented at the 2022 American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, continuation of enzalutamide in conjunction with docetaxel was associated with modestly but significantly better PFS (defined by radiographic or clinical progression or death, median 9.53 versus 8.28, HR 0.72, 95% CI 0.53-0.96). Combined therapy also improved median time to PSA progression (8.44 versus 6.24 months); overall survival endpoints were not reported. These benefits came at the cost of more treatment related toxicity; treatment-emergent adverse effects were reported in more patients receiving combined therapy (49 versus 39 percent), and there were more deaths in this group as well (13 versus 7, 9.6 versus 5.2 percent). We await more mature data from this trial in order to define which populations of patients stand to benefit the most.</p><p class="headingAnchor" id="H2478645527"><span class="h2">Abiraterone versus enzalutamide</span><span class="headingEndMark"> — </span>There are limited data comparing <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in the initial management of patients with CRPC, and the choice of one agent over another should be based on toxicity profiles and patient-specific factors, including reimbursement from third-party payers. Many insurers are requiring abiraterone first because it is available as a generic drug and is somewhat less expensive.</p><p>Results are available from a randomized phase II trial in which 202 treatment-naïve males with metastatic CRPC were assigned to <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> followed by crossover to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> at the time of progression, or the opposite sequence [<a href="#rid62">62</a>]. Although there was a higher prostate-specific antigen (PSA) response rate with first-line enzalutamide (82 versus 68 percent), the time to PSA progression was not significantly different (10.2 versus 11.2 months). Furthermore, there was a significant benefit to initial treatment with abiraterone in terms of time to PSA progression after crossover (median 3.5 versus 1.7 months) and PSA response to second-line therapy (36 versus 4 percent). The most common grade 3 or 4 adverse events for first-line therapy were hypertension (23 versus 13 percent for initial abiraterone versus enzalutamide), fatigue (6 versus 2 percent), and increased alanine aminotransferase (6 versus 1 percent). The most common grade 3 or 4 adverse events with second-line therapy were hypertension (18 versus 13 percent for second-line enzalutamide versus abiraterone), fatigue (5 versus 3 percent), back pain (3 versus 4 percent), and extremity pain (4 versus 1 percent). In our view, these are very minor differences.</p><p class="headingAnchor" id="H422073960"><span class="h2">Combining abiraterone and an AR antagonist</span><span class="headingEndMark"> — </span>Until further information becomes available, we suggest not pursuing combined therapy with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> in males with CRPC.</p><p>Androgen synthesis inhibitors (such as <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a>) and androgen receptor antagonists (such as <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>) target androgen-based pathways by different mechanisms, and mechanisms of resistance also differ. Several retrospective studies indicate that either using abiraterone after enzalutamide or using enzalutamide after abiraterone in CRPC has limited activity [<a href="#rid40">40-42</a>]. There are no data on sequential use of abiraterone and apalutamide. (See <a class="local">'Prior abiraterone therapy'</a> above and <a class="local">'Prior enzalutamide therapy'</a> above.)</p><p>The hypothesis that coadministration might forestall disease resistance or prolong survival has been addressed in the following studies:</p><p class="bulletIndent1"><span class="glyph">●</span>The phase III ALLIANCE A031201 trial, which compared <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> 160 mg daily plus <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> (1000 mg daily) and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> 5 mg twice daily versus enzalutamide alone in 1311 males with progressive metastatic CRPC [<a href="#rid63">63</a>]. In a preliminary report presented at the 2019 annual ASCO meeting, combined therapy did not improve overall survival (32.7 versus 33.6 months) or the 50 percent prostate-specific antigen (PSA) decline rate (77 versus 80 percent), and it increased rates of grade 3 or 4 hypertension, fatigue, transaminitis, and hypokalemia.</p><p></p><p class="bulletIndent1">Whether this approach has clinical utility is the subject of a second ongoing randomized trial comparing combined therapy versus <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> alone.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>On the other hand, modest benefit for combined therapy with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> was suggested in the phase III ACIS trial, in which 982 males with progressive metastatic chemotherapy-naïve metastatic CRPC receiving ongoing ADT alone were randomly assigned to apalutamide plus abiraterone and <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> or placebo plus abiraterone plus prednisone [<a href="#rid64">64</a>]. At a median follow-up of 55 months, the median radiographic PFS (the primary endpoint) was prolonged by six months by the addition of apalutamide (24 versus 16.6 months, HR 0.70 [95% CI 0.60-0.83]), and there was a modest but significantly higher rate of PSA response as well (decline of at least 50 percent, 79 versus 73 percent); the difference in median overall survival was not significant (median 36.2 versus 33.7 months, HR 0.95 [95% CI 0.81-1.11]). Combined therapy was associated with more frequent grade 3 or 4 treatment-related adverse effects, although there were fewer grade 5 (fatal) toxicities in the combined therapy group (17 versus 37 events, 3 versus 8 percent).</p><p></p><p class="headingAnchor" id="H3251448557"><span class="h2">Combining enzalutamide with a PARP inhibitor</span><span class="headingEndMark"> — </span>Use of the poly(ADP-ribose) polymerase (PARP) inhibitor <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">talazoparib</a> concurrently with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> has shown PFS benefit relative to enzalutamide alone, but further study and/or regulatory approval are needed prior to routine clinical use of this strategy.</p><p>In the TALAPRO-2 trial, 805 patients with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer receiving ongoing ADT were randomly assigned to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and <a class="drug drug_general" data-topicid="119387" href="/z/d/drug information/119387.html" rel="external">talazoparib</a> or enzalutamide and placebo [<a href="#rid65">65</a>]. Approximately 80 percent were taxane chemotherapy-naïve. At a median follow-up of 24.6 months, PFS was not reached in the talazoparib group and was 21.9 months in the placebo group (HR 0.63, 95% CI 0.51-0.78). Benefits were observed both among those with homologous recombination repair deficient tumors (HR 0.46) and among those non-deficient or unknown status (0.70). Overall survival results are immature. In the talazoparib group, 59 percent had grade ≥3 treatment-related adverse events, versus 18 percent in the placebo group.</p><p>While these results are promising, longer term data are needed.</p><p class="headingAnchor" id="H1149248666"><span class="h1">PATIENTS WITH NONMETASTATIC CRPC</span><span class="headingEndMark"> — </span>For males with nonmetastatic CRPC, phase III trials with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>, and <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">darolutamide</a> have shown that all three drugs significantly prolong metastasis-free survival and delay the use of other antitumor therapy. In this setting, the efficacy of these three agents has not been compared directly, but it appears to be similar. Differences in the safety and side effect profile may drive treatment decisions [<a href="#rid66">66</a>]. Notably, darolutamide has not been reported to induce fewer central nervous system side effects compared with enzalutamide and, to a lesser extent, apalutamide. All three agents carry a risk of drug-drug interactions, which should be examined closely prior to choosing one agent over another.</p><p class="headingAnchor" id="H1767881070"><span class="h2">Enzalutamide</span><span class="headingEndMark"> — </span>Data on the efficacy of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in males with CRPC without detectable distant metastases come from the PROSPER trial, in which 1401 males with high-risk CRPC, a PSA doubling time ≤10 months, and a serum PSA ≥2 ng/mL, but without metastatic disease (M0) were randomly assigned to enzalutamide or placebo, while continuing on ADT [<a href="#rid67">67</a>]. The following were noted:</p><p class="bulletIndent1"><span class="glyph">●</span>The primary endpoint of the trial was metastasis-free survival, which was prolonged with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> compared with placebo (36.6 versus 14.7 months, HR 0.29, 95% CI 0.24-0.35).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Time to first use of a new antineoplastic agent, a secondary endpoint, was prolonged (39.6 versus 17.7 months, HR 0.21, 95% CI 0.17-0.26), and time to PSA progression was significantly prolonged (37.2 versus 3.9 months, HR 0.07, 95% CI 0.05-0.08).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A later analysis also demonstrated improved overall survival of <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> plus ADT over ADT alone (median 67 versus 56 months, HR 0.73, 95% CI 0.61-0.89) [<a href="#rid68">68</a>].</p><p></p><p>Largely based on the results of the PROSPER trial, <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> was approved by the US Food and Drug Administration (FDA) for treatment of all males with nonmetastatic CRPC.</p><p class="headingAnchor" id="H147795442"><span class="h2">Apalutamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">Apalutamide</a> binds to the androgen binding site in the androgen receptor and has shown considerable activity against CRPC in both the metastatic [<a href="#rid69">69</a>] and nonmetastatic setting [<a href="#rid70">70,71</a>]. Its mechanism of action and efficacy profile are very similar to <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>; however, it has fewer central nervous system toxicities.</p><p>The bulk of the data are in males with nonmetastatic CRPC. In the phase III SPARTAN trial, 1207 males with nonmetastatic CRPC were randomly assigned to <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> or placebo in a 2:1 ratio while continuing ADT [<a href="#rid70">70</a>]. Patient eligibility requirements included the absence of metastases and a PSA doubling time of ≤10 months. At a median follow-up of 20 months, key results included the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Metastasis-free survival, the primary endpoint of the trial, was increased compared with placebo (median 40.5 versus 16.2 months, HR 0.28, 95% CI 0.23-0.35). Secondary endpoints, including time to metastasis, progression-free survival, and time to PSA progression, were also significantly better with <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>. In a later analysis, overall survival was also better with apalutamide (median 73.9 versus 59.9, HR for death 0.78, 95% CI 0.64-0.96) [<a href="#rid72">72</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Treatment was generally well tolerated. The most common grade 3 to 4 side effects associated with <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> were hypertension and rash (14.3 and 5.2 percent, respectively). Other noteworthy side effects attributed to the study drug included fatigue, falls, fractures, hypothyroidism, and mental impairment (overall incidence 30, 16, 12, 8, and 5 percent, respectively). Cerebrovascular events occurred in 4.7 percent of patients treated with apalutamide, compared with 0.8 percent of those receiving placebo [<a href="#rid73">73</a>]. Seizures occurred in only 0.2 percent of patients treated with apalutamide.</p><p></p><p>Largely based on these data, <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> was approved by the FDA for treatment of nonmetastatic CRPC.</p><p class="headingAnchor" id="H1443578645"><span class="h2">Darolutamide</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">Darolutamide</a> (ODM-221) is an androgen receptor antagonist with a distinct structure that offers the potential for fewer and less severe toxic effects than either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> because of its low penetration of the blood-brain barrier and low binding affinity for gamma-aminobutyric acid type A (GABA<sub>A</sub>) receptors (which are thought responsible for the tendency of other androgen receptor antagonists to induce seizures) [<a href="#rid74">74,75</a>]. In addition, darolutamide also blocks the activity of mutant androgen receptors that arise in response to antiandrogen therapies, which confer resistance to other androgen receptor antagonists.</p><p>Efficacy in metastatic CRPC was initially suggested in a combined phase I/II trial [<a href="#rid76">76</a>]. Efficacy in nonmetastatic CRPC was later shown in a double-blind phase III trial (ARAMIS) in which 1509 males with nonmetastatic CRPC and a PSA doubling time of &lt;10 months were randomly assigned to <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">darolutamide</a> (600 mg orally twice daily) or placebo; both groups continued primary ADT [<a href="#rid77">77</a>]. Median metastasis-free survival (the primary endpoint) was significantly longer with darolutamide (40.4 versus 18.4 months, HR 0.41, 95% CI 0.31-0.50), and there were significant benefits with regard to all secondary endpoints, including overall survival (HR 0.69, 95% CI 0.53-0.88) [<a href="#rid78">78</a>], time to pain progression, time to need for cytotoxic chemotherapy, and time to a symptomatic skeletal event. Treatment was well tolerated overall, and darolutamide was not associated with a higher incidence of seizures, falls, fractures, cognitive disorder, or hypertension.</p><p>Largely based on these data, <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">darolutamide</a> was approved by the FDA for treatment of nonmetastatic CRPC [<a href="#rid79">79</a>]. A reduced initial dose is recommended for individuals with severe renal impairment (estimated glomerular filtration rate [eGFR] &lt;29 mL/min/1.73 m<sup>2</sup>) or moderate hepatic impairment (Child-Pugh class B cirrhosis  (<a class="graphic graphic_table graphicRef78401" href="/z/d/graphic/78401.html" rel="external">table 5</a>)).</p><p class="headingAnchor" id="H464474295"><span class="h2">Is any one drug superior to the others in nonmetastatic CRPC?</span><span class="headingEndMark"> — </span>For males with nonmetastatic CRPC, phase III trials with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>, and <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">darolutamide</a> have shown that all three drugs significantly prolong metastasis-free survival and overall survival, and delay the use of other antitumor therapy. In this setting, the efficacy of these three agents has not been compared directly, but it appears to be similar. Differences in the safety and side effect profile may drive treatment decisions [<a href="#rid66">66</a>].</p><p><a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">Darolutamide</a> has been reported to induce fewer side effects compared with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>, although the data are less than definitive. A systematic review and meta-analysis of all three studies concluded that there was no difference in prostate cancer outcomes among any of the three drugs, and no statistically significant differences in the adverse event profiles [<a href="#rid80">80</a>]. An indirect analysis of individual patient data from the three trials also came to this conclusion [<a href="#rid81">81</a>]. However, a separate analysis of the published data from all three trials emphasized the remarkable differences in adverse event reporting in the trials, as well as differences in the absolute adverse event risks in all three placebo arms, concluding that the available data are insufficient to differentiate adverse event profiles of these agents in nonmetastatic CRPC [<a href="#rid82">82</a>].</p><p>All three agents carry a risk of drug-drug interactions, which should be examined closely prior to choosing one agent over another.</p><p class="headingAnchor" id="H1682704250"><span class="h1">ASSESSMENT DURING TREATMENT</span><span class="headingEndMark"> — </span>For males with CRPC who are undergoing systemic therapy, periodic assessment should be geared toward identifying signs and symptoms of disease progression, as well as the side effects of treatment. Serial evaluation of serum prostate-specific antigen (PSA) is the mainstay of testing. Consensus-based guidelines from the National Comprehensive Cancer Network (NCCN) recommend testing PSA every three to six months during treatment for advanced prostate cancer [<a href="#rid83">83</a>]. Most clinicians make decisions about the need for radiographic evaluation based on changes in PSA values and/or the development of new symptoms. Therapeutic changes are usually not made based on a rising PSA alone.</p><p>Assessment strategies during treatment for CRPC are discussed in more detail separately. (See  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)", section on 'Assessment during treatment'</a>.)</p><p class="headingAnchor" id="H2375726802"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117831.html" rel="external">"Society guideline links: Diagnosis and management of prostate cancer"</a>.)</p><p class="headingAnchor" id="H1385299369"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rationale for continued targeting of androgen receptor pathways</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Despite high response rates to androgen deprivation therapy (ADT) in males with advanced prostate cancer, nearly all eventually develop progressive castration-resistant prostate cancer (CRPC). Despite castration "resistance," androgen-based pathways can continue to stimulate disease progression in males with CRPC. This understanding has led to the development of alternative treatments that target the androgen pathway by inhibiting the enzymes responsible for androgen production, as well as agents that inhibit the androgen receptor. (See <a class="local">'Rationale'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The clinical role of treatments for CRPC that target the androgen pathway is evolving. Contemporary research in males with CRPC has led to the development of multiple agents that have significantly improved overall survival in phase III trials conducted in individuals with metastatic and nonmetastatic CRPC  (<a class="graphic graphic_table graphicRef127196" href="/z/d/graphic/127196.html" rel="external">table 2</a> and <a class="graphic graphic_table graphicRef127197" href="/z/d/graphic/127197.html" rel="external">table 1</a>). These agents have not been compared with each other, and the appropriate sequencing of them in males with advanced disease is not established. The factors affecting the choice and sequence of therapies in the setting of CRPC are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/112896.html" rel="external">"Overview of the treatment of castration-resistant prostate cancer (CRPC)"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with metastatic CRPC</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The efficacy of both <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> and <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in conjunction with continued ADT have been established in placebo-controlled trials for males with metastatic CRPC, both in the docetaxel-naïve and chemotherapy refractory settings. (See <a class="local">'Abiraterone'</a> above and <a class="local">'Enzalutamide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>All males receiving <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> should also receive <a class="drug drug_general" data-topicid="9809" href="/z/d/drug information/9809.html" rel="external">prednisone</a> to mitigate mineralocorticoid excess. The standard dose is 5 mg twice daily, and we do not use either lower prednisone doses or substitute <a class="drug drug_general" data-topicid="9334" href="/z/d/drug information/9334.html" rel="external">dexamethasone</a> for prednisone. (See <a class="local">'Concurrent glucocorticoid therapy'</a> above.)</p><p></p><p class="bulletIndent2">There are only limited data comparing <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> in the initial management of patients with metastatic CRPC, and the choice of one agent over another should be individualized and based on toxicity profiles and patient-specific factors, including reimbursement from third-party payers. Many insurers are requiring abiraterone first because it is available as a generic drug and is somewhat less expensive. (See <a class="local">'Abiraterone versus enzalutamide'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Until further information becomes available, we suggest not pursuing combined therapy with <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> plus either <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> or <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a> in males with CRPC (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). (See <a class="local">'Combining abiraterone and an AR antagonist'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although the practice of switching between <a class="drug drug_general" data-topicid="16083" href="/z/d/drug information/16083.html" rel="external">abiraterone</a> and <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> after progression with the other is common, particularly to delay initiation of chemotherapy, few data are available to support meaningful benefit from use of abiraterone after failure of enzalutamide and vice versa, and we do not routinely use this approach. (See <a class="local">'Prior enzalutamide therapy'</a> above and <a class="local">'Prior abiraterone therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Patients with nonmetastatic CRPC</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients with nonmetastatic CRPC, phase III trials with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a>, <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>, and <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">darolutamide</a> have shown that all three drugs significantly prolong metastasis-free survival and overall survival, and delay the use of other antitumor therapy. In this setting, the efficacy of these three agents has not been compared directly, but it appears to be similar  (<a class="graphic graphic_table graphicRef127196" href="/z/d/graphic/127196.html" rel="external">table 2</a>). (See <a class="local">'Patients with nonmetastatic CRPC'</a> above.)</p><p></p><p class="bulletIndent2">Differences in the safety profile may drive treatment decisions. <a class="drug drug_general" data-topicid="122022" href="/z/d/drug information/122022.html" rel="external">Darolutamide</a> has not been reported to induce fewer central nervous system side effects compared with <a class="drug drug_general" data-topicid="86370" href="/z/d/drug information/86370.html" rel="external">enzalutamide</a> and, to a lesser extent, <a class="drug drug_general" data-topicid="116885" href="/z/d/drug information/116885.html" rel="external">apalutamide</a>. All three agents carry a risk of drug-drug interactions, which should be examined closely prior to choosing one agent over another. (See <a class="local">'Is any one drug superior to the others in nonmetastatic CRPC?'</a> above.)</p><p></p><p class="headingAnchor" id="H2881342014"><span class="h1">ACKNOWLEDGMENTS</span></p><p>The UpToDate editorial staff acknowledges Charles J Ryan, MD, who contributed to earlier versions of this topic review.</p><p>We are saddened by the death of Nicholas Vogelzang, MD, who passed away in September 2022. UpToDate gratefully acknowledges Dr. Vogelzang's role as Section Editor on this topic, and his dedicated and longstanding involvement with the UpToDate program.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68:4447.</a></li><li><a class="nounderline abstract_t">Barrie SE, Potter GA, Goddard PM, et al. Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase). J Steroid Biochem Mol Biol 1994; 50:267.</a></li><li><a class="nounderline abstract_t">Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer. J Clin Oncol 2009; 27:3742.</a></li><li><a class="nounderline abstract_t">Potter GA, Barrie SE, Jarman M, Rowlands MG. Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer. J Med Chem 1995; 38:2463.</a></li><li><a class="nounderline abstract_t">Visakorpi T, Hyytinen E, Koivisto P, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet 1995; 9:401.</a></li><li><a class="nounderline abstract_t">Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10:33.</a></li><li><a class="nounderline abstract_t">Edwards J, Krishna NS, Grigor KM, Bartlett JM. Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer. Br J Cancer 2003; 89:552.</a></li><li><a class="nounderline abstract_t">Gregory CW, Johnson RT Jr, Mohler JL, et al. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res 2001; 61:2892.</a></li><li><a class="nounderline abstract_t">Watson PA, Chen YF, Balbas MD, et al. Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor. Proc Natl Acad Sci U S A 2010; 107:16759.</a></li><li><a class="nounderline abstract_t">Guo Z, Yang X, Sun F, et al. A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth. Cancer Res 2009; 69:2305.</a></li><li><a class="nounderline abstract_t">McKay RR, Kwak L, Crowdis JP, et al. Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance. Clin Cancer Res 2021; 27:3610.</a></li><li><a class="nounderline abstract_t">Sperger JM, Emamekhoo H, McKay RR, et al. Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer. J Clin Oncol 2021; 39:2926.</a></li><li><a class="nounderline abstract_t">Antonarakis ES, Lu C, Wang H, et al. AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer. N Engl J Med 2014; 371:1028.</a></li><li><a class="nounderline abstract_t">Antonarakis ES, Lu C, Luber B, et al. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide. J Clin Oncol 2017; :JCO2016701961.</a></li><li><a class="nounderline abstract_t">Armstrong AJ, Halabi S, Luo J, et al. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study. J Clin Oncol 2019; 37:1120.</a></li><li><a class="nounderline abstract_t">Antonarakis ES, Lu C, Luber B, et al. Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer. JAMA Oncol 2015; 1:582.</a></li><li><a class="nounderline abstract_t">de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 2011; 364:1995.</a></li><li><a class="nounderline abstract_t">Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2012; 13:983.</a></li><li><a class="nounderline abstract_t">Logothetis CJ, Basch E, Molina A, et al. Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial. Lancet Oncol 2012; 13:1210.</a></li><li><a class="nounderline abstract_t">Rathkopf DE, Smith MR, de Bono JS, et al. Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302). Eur Urol 2014; 66:815.</a></li><li><a class="nounderline abstract_t">Ryan CJ, Smith MR, Fizazi K, et al. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol 2015; 16:152.</a></li><li><a class="nounderline abstract_t">Goodman OB Jr, Flaig TW, Molina A, et al. Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2014; 17:34.</a></li><li><a class="nounderline abstract_t">Ryan CJ, Shah S, Efstathiou E, et al. Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response. Clin Cancer Res 2011; 17:4854.</a></li><li><a class="nounderline abstract_t">Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med 2013; 368:138.</a></li><li><a class="nounderline abstract_t">Basch E, Autio K, Ryan CJ, et al. Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial. Lancet Oncol 2013; 14:1193.</a></li><li><a class="nounderline abstract_t">Attard G, Borre M, Gurney H, et al. Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment. J Clin Oncol 2018; 36:2639.</a></li><li><a class="nounderline abstract_t">de Wit R, de Bono J, Sternberg CN, et al. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer. N Engl J Med 2019; 381:2506.</a></li><li><a class="nounderline abstract_t">Bourke L, Chico TJ, Albertsen PC, et al. Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved. Heart 2012; 98:345.</a></li><li><a class="nounderline abstract_t">Lu-Yao G, Nikita N, Keith SW, et al. Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities. Eur Urol 2020; 77:158.</a></li><li><a class="nounderline abstract_t">Attard G, Merseburger AS, Arlt W, et al. Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study. JAMA Oncol 2019; 5:1159.</a></li><li><a class="nounderline abstract_t">Fizazi K, Chi KN, de Bono JS, et al. Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016; 70:438.</a></li><li><a class="nounderline abstract_t">Szmulewitz RZ, Peer CJ, Ibraheem A, et al. Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer. J Clin Oncol 2018; 36:1389.</a></li><li><a class="nounderline abstract_t">Tannock IF. Low-Fat Abiraterone Food Effect Is of Great Consequence. J Clin Oncol 2018; 36:3058.</a></li><li><a class="nounderline abstract_t">Groenland SL, van Nuland M, Bergman AM, et al. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer 2020; 130:32.</a></li><li><a class="nounderline abstract_t">Patel A, Tannock IF, Srivastava P, et al. Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets. JCO Glob Oncol 2020; 6:382.</a></li><li><a class="nounderline abstract_t">Carton E, Noe G, Huillard O, et al. Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients. Eur J Cancer 2017; 72:54.</a></li><li class="breakAll">National Comprehensive Cancer Network (NCCN). NCCN clinical practice guidelines in oncology. Available at: https://www.nccn.org/professionals/physician_gls/pdf/gist.pdf (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Xiong X, Qiu S, Yi X, et al. Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review. Urol Oncol 2021; 39:754.</a></li><li><a class="nounderline abstract_t">Smith MR, Saad F, Rathkopf DE, et al. Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. Eur Urol 2017; 72:10.</a></li><li><a class="nounderline abstract_t">Loriot Y, Bianchini D, Ileana E, et al. Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100). Ann Oncol 2013; 24:1807.</a></li><li><a class="nounderline abstract_t">Noonan KL, North S, Bitting RL, et al. Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide. Ann Oncol 2013; 24:1802.</a></li><li><a class="nounderline abstract_t">Bianchini D, Lorente D, Rodriguez-Vida A, et al. Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone. Eur J Cancer 2014; 50:78.</a></li><li><a class="nounderline abstract_t">Azad AA, Eigl BJ, Murray RN, et al. Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients. Eur Urol 2015; 67:23.</a></li><li><a class="nounderline abstract_t">de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for ≥24 weeks in Europe. Eur Urol 2018; 74:37.</a></li><li><a class="nounderline abstract_t">Scher HI, Beer TM, Higano CS, et al. Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet 2010; 375:1437.</a></li><li><a class="nounderline abstract_t">Rathkopf D, Liu G, Carducci MA, et al. Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer. Clin Cancer Res 2011; 17:880.</a></li><li><a class="nounderline abstract_t">Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 2012; 367:1187.</a></li><li><a class="nounderline abstract_t">Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol 2014; 15:1147.</a></li><li class="breakAll">XTANDI (enzalutamide) capsules for oral use. Available at: http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203415lbl.pdf?et_cid=29930410&amp;et_rid=463634184&amp;linkid=http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda_docs%2flabel%2f2012%2f203415lbl.pdf (Accessed on September 04, 2012).</li><li><a class="nounderline abstract_t">Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol 2014; 25:429.</a></li><li><a class="nounderline abstract_t">Zhao JL, Fizazi K, Saad F, et al. The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial. Clin Cancer Res 2022; 28:860.</a></li><li><a class="nounderline abstract_t">Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med 2014; 371:424.</a></li><li><a class="nounderline abstract_t">Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol 2015; 16:509.</a></li><li><a class="nounderline abstract_t">Evans CP, Higano CS, Keane T, et al. The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer. Eur Urol 2016; 70:675.</a></li><li><a class="nounderline abstract_t">Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol 2017; 71:151.</a></li><li><a class="nounderline abstract_t">Armstrong AJ, Lin P, Tombal B, et al. Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial. Eur Urol 2020; 78:347.</a></li><li><a class="nounderline abstract_t">Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol 2016; 17:153.</a></li><li><a class="nounderline abstract_t">Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. J Clin Oncol 2016; 34:2098.</a></li><li><a class="nounderline abstract_t">Iacovelli R, Ciccarese C, Bria E, et al. The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer. Clin Genitourin Cancer 2018; 16:e645.</a></li><li><a class="nounderline abstract_t">Higano CS. Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer. N Engl J Med 2020; 382:2257.</a></li><li class="breakAll">Merseburger AS. Attard G, Boysen G, et al. A randomized, double-blind, placebo (PBO)-controlled, phase 3b study of the efficacy and safety of continuing enzalutamide (ENZA) in chemotherapy-naïve, metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with docetaxel (DOC) plus prednisolone (PDN) who have progressed on ENZA: PRESIDE). J Clin Oncol 40, 2022 (suppl 6; abstr 15). Abstraact available online at https://meetinglibrary.asco.org/record/206039/abstract (Accessed on March 15, 2022).</li><li><a class="nounderline abstract_t">Khalaf DJ, Annala M, Taavitsainen S, et al. Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial. Lancet Oncol 2019; 20:1730.</a></li><li><a class="nounderline abstract_t">Morris MJ, Heller G, Bryce AH, et al. Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC). J Clin Oncol 2019; 37S:ASCO #5008.</a></li><li><a class="nounderline abstract_t">Saad F, Efstathiou E, Attard G, et al. Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study. Lancet Oncol 2021; 22:1541.</a></li><li><a class="nounderline abstract_t">Agarwal N, Azad AA, Carles J, et al. Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial. Lancet 2023; 402:291.</a></li><li><a class="nounderline abstract_t">Heidegger I, Brandt MP, Heck MM. Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best? Urol Oncol 2020; 38:129.</a></li><li><a class="nounderline abstract_t">Hussain M, Fizazi K, Saad F, et al. Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2018; 378:2465.</a></li><li><a class="nounderline abstract_t">Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2020; 382:2197.</a></li><li><a class="nounderline abstract_t">Rathkopf DE, Antonarakis ES, Shore ND, et al. Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone. Clin Cancer Res 2017; 23:3544.</a></li><li><a class="nounderline abstract_t">Smith MR, Saad F, Chowdhury S, et al. Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer. N Engl J Med 2018; 378:1408.</a></li><li><a class="nounderline abstract_t">Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer. Ann Oncol 2019; 30:1813.</a></li><li><a class="nounderline abstract_t">Smith MR, Saad F, Chowdhury S, et al. Apalutamide and Overall Survival in Prostate Cancer. Eur Urol 2021; 79:150.</a></li><li class="breakAll">US prescribing information for apalutamide available online at https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/210951s004lbl.pdf (Accessed on November 30, 2020).</li><li><a class="nounderline abstract_t">Moilanen AM, Riikonen R, Oksala R, et al. Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies. Sci Rep 2015; 5:12007.</a></li><li><a class="nounderline abstract_t">Zurth C, Sandman S, Trummel D, et al. Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography. J Clin Oncol 2019; 37S:ASCO #156.</a></li><li><a class="nounderline abstract_t">Fizazi K, Massard C, Bono P, et al. Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial. Lancet Oncol 2014; 15:975.</a></li><li><a class="nounderline abstract_t">Fizazi K, Shore N, Tammela TL, et al. Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer. N Engl J Med 2019; 380:1235.</a></li><li><a class="nounderline abstract_t">Fizazi K, Shore N, Tammela TL, et al. Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide. N Engl J Med 2020; 383:1040.</a></li><li class="breakAll">FDA approves darolutamide for non-metastatic castration-resistant prostate cancer. Available at: https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-darolutamide-non-metastatic-castration-resistant-prostate-cancer (Accessed on August 01, 2019).</li><li><a class="nounderline abstract_t">Kumar J, Jazayeri SB, Gautam S, et al. Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis. Urol Oncol 2020; 38:826.</a></li><li><a class="nounderline abstract_t">Halabi S, Jiang S, Terasawa E, et al. Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer. J Urol 2021; 206:298.</a></li><li><a class="nounderline abstract_t">Drago JZ, Gönen M, Thanarajasingam G, et al. Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer. J Natl Cancer Inst 2021; 113:553.</a></li><li class="breakAll">NCCN Clinical Practice Guidelines in Oncology. Available at: https://www.nccn.org/professionals/physician_gls/default.aspx (Accessed on August 15, 2019).</li></ol></div><div id="topicVersionRevision">Topic 16351 Version 90.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18519708" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7918112" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19470933" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7608911" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Novel steroidal inhibitors of human cytochrome P45017 alpha (17 alpha-hydroxylase-C17,20-lyase): potential agents for the treatment of prostatic cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7795646" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : In vivo amplification of the androgen receptor gene and progression of human prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14702632" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Molecular determinants of resistance to antiandrogen therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12888829" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Androgen receptor gene amplification and protein expression in hormone refractory prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11306464" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20823238" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Constitutively active androgen receptor splice variants expressed in castration-resistant prostate cancer require full-length androgen receptor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19244107" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : A novel androgen receptor splice variant is up-regulated during prostate cancer progression and promotes androgen depletion-resistant growth.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33849963" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Phase II Multicenter Study of Enzalutamide in Metastatic Castration-Resistant Prostate Cancer to Identify Mechanisms Driving Resistance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34197212" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Prospective Evaluation of Clinical Outcomes Using a Multiplex Liquid Biopsy Targeting Diverse Resistance Mechanisms in Metastatic Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25184630" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28384066" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30865549" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26181238" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21612468" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Abiraterone and increased survival in metastatic prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22995653" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23142059" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Effect of abiraterone acetate and prednisone compared with placebo and prednisone on pain control and skeletal-related events in patients with metastatic castration-resistant prostate cancer: exploratory analysis of data from the COU-AA-301 randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24647231" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25601341" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24080993" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exploratory analysis of the visceral disease subgroup in a phase III study of abiraterone acetate in metastatic castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21632851" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23228172" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Abiraterone in metastatic prostate cancer without previous chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24075621" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30028657" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Abiraterone Alone or in Combination With Enzalutamide in Metastatic Castration-Resistant Prostate Cancer With Rising Prostate-Specific Antigen During Enzalutamide Treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31566937" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22155645" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Cardiovascular risk in androgen suppression: underappreciated, under-researched and unresolved.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31420248" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Mortality and Hospitalization Risk Following Oral Androgen Signaling Inhibitors Among Men with Advanced Prostate Cancer by Pre-existing Cardiovascular Comorbidities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31246234" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Assessment of the Safety of Glucocorticoid Regimens in Combination With Abiraterone Acetate for Metastatic Castration-Resistant Prostate Cancer: A Randomized, Open-label Phase 2 Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26965562" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Low Incidence of Corticosteroid-associated Adverse Events on Long-term Exposure to Low-dose Prednisone Given with Abiraterone Acetate to Patients with Metastatic Castration-resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29590007" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30188783" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Low-Fat Abiraterone Food Effect Is of Great Consequence.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32172196" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32125899" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Low-Dose Abiraterone in Metastatic Prostate Cancer: Is It Practice Changing? Facts and Facets.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027516" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28027516" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Relation between plasma trough concentration of abiraterone and prostate-specific antigen response in metastatic castration-resistant prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34330654" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Steroid switch after progression on abiraterone plus prednisone in patients with metastatic castration-resistant prostate cancer: A systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28314611" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23576708" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Antitumour activity of abiraterone acetate against metastatic castration-resistant prostate cancer progressing after docetaxel and enzalutamide (MDV3100).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23585511" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Clinical activity of abiraterone acetate in patients with metastatic castration-resistant prostate cancer progressing after enzalutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24074764" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Antitumour activity of enzalutamide (MDV3100) in patients with metastatic castration-resistant prostate cancer (CRPC) pre-treated with docetaxel and abiraterone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25018038" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Efficacy of enzalutamide following abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28844372" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Antitumour Activity and Safety of Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Abiraterone Acetate Plus Prednisone for≥24 weeks in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20398925" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21131556" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Phase I dose-escalation study of the novel antiandrogen BMS-641988 in patients with castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22894553" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Increased survival with enzalutamide in prostate cancer after chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104109" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25104109" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24478320" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34965947" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24881730" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Enzalutamide in metastatic prostate cancer before chemotherapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25888263" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27006332" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The PREVAIL Study: Primary Outcomes by Site and Extent of Baseline Disease for Enzalutamide-treated Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27477525" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32527692" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Five-year Survival Prediction and Safety Outcomes with Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer from the PREVAIL Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26774508" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26811535" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29339044" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469186" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469186" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Cardiovascular Disease and Androgen Axis-Targeted Drugs for Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31727538" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Alliance A031201: A phase III trial of enzalutamide (ENZ) versus enzalutamide, abiraterone, and prednisone (ENZ/AAP) for metastatic castration resistant prostate cancer (mCRPC)</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/34600602" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37285865" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31953000" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Treatment of non-metastatic castration resistant prostate cancer in 2020: What is the best?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29949494" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32469184" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28213364" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Safety and Antitumor Activity of Apalutamide (ARN-509) in Metastatic Castration-Resistant Prostate Cancer with and without Prior Abiraterone Acetate and Prednisone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29420164" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31560066" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Apalutamide and overall survival in non-metastatic castration-resistant prostate cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32907777" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Apalutamide and Overall Survival in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32907777" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Apalutamide and Overall Survival in Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26137992" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Higher blood–brain barrier penetration of [14C]apalutamide and [14C]enzalutamide compared to [14C]darolutamide in rats using whole-body autoradiography</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24974051" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30763142" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32905676" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32905676" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nonmetastatic, Castration-Resistant Prostate Cancer and Survival with Darolutamide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32605736" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Comparative efficacy of apalutamide darolutamide and enzalutamide for treatment of non-metastatic castrate-resistant prostate cancer: A systematic review and network meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33818140" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Indirect Comparison of Darolutamide versus Apalutamide and Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32857839" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Inferences About Drug Safety in Phase III Trials in Oncology: Examples From Advanced Prostate Cancer.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
